ISLAND PHARMACEUTICALS LTD
ASX: ILA (ISLAND PHA FPO [ILA])
Last update: 13 hours ago0.430
0.01 (2.38%)
| Previous Close | 0.420 |
| Volume | 93,852 |
| Price / Sales | 411.23 |
| Price / Book | 9.46 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,556.27% |
| Diluted EPS (TTM) | -0.030 |
| Quarterly Revenue Growth (YOY) | -89.90% |
| Total Debt/Equity (MRQ) | 27.78% |
| Current Ratio (MRQ) | 10.27 |
| Operating Cash Flow (TTM) | -2.89 M |
| Levered Free Cash Flow (TTM) | -1.71 M |
| Return on Assets (TTM) | -65.80% |
| Return on Equity (TTM) | -143.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ISLAND PHA FPO [ILA] | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 60.56% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |